This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Thoolen, B. Articles by De Haan, M. Search for Related Content PubMed PubMed Citation Articles by Thoolen, B. Articles by De Haan, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Carcinoid Tumors Stomach Cancer Hazardous Substances DB OMEPRAZOLE Social Bookmarking                         What's this?

Gastric Neuroendocrine Tumors in a 2-Year Oncogenicity Study With CD-1 Mice

Drug Safety Department, Solvay Pharmaceuticals Research Laboratories, Weesp, The Netherlands, bob.thoolen@ solvay.com

Henk Koster

Drug Safety Department, Solvay Pharmaceuticals Research Laboratories, Weesp, The Netherlands

Anton Van Kolfschoten

Drug Safety Department, Solvay Pharmaceuticals Research Laboratories, Weesp, The Netherlands

Martin De Haan

Drug Safety Department, Solvay Pharmaceuticals Research Laboratories, Weesp, The Netherlands

Descriptions of two rare gastric neuroendocrine tumors (carcinoids) of enterochromaffin (ECL) cells in CD-1 mice (2/50) from a 104-week oncogenicity study of a serotonergic/dopaminergic compound are presented. These tumors were detected at necropsy and confirmed by histopathology in hematoxylin and eosin- and Chromogranin A-stained slides. ECL cell counts of the glandular stomachs were determined by quantitative image analysis and did not reveal any hyperplastic changes as possible predisposing lesions for carcinoid formation. To investigate the possibility of drug-induced hypergastrinemi a as the cause of tumor formation of ECL cells, gastrin blood levels were measured after treating mice for 7 days with the test substance. In this study, Omeprazole, the positive control, raised gastrin levels, while the test material did not. It was concluded that these two tumors were an example of "late-life"-occurring, spontaneous neuroendocrine tumors in the stomachs of aged CD-1 mice.

Key Words: Carcinoids • CD-1 mice • Chromogranin A • ECL cells • gastrin • neuroendocrine tumor • stomach.

References

• Belaiche J., Delwaide J., Louis E., Gast P. ( 1993). Enterochromaffin-like cells and their receptors: Physiological role and physiopathologica l significance. Acta Gastroenterol Belg 56: 3— 4.
• Betton GR, Dormer CS, Wells T., Pert P., Price CA, Buckley P. (1987). Fundic mucosal ECL hyperplasia and carcinoids in rodents following chronic administration of the histamine H2-receptor antagonist SK&F 93479 and other antisecretory agents. Toxicol Pathol 15: 365.
• Betton GR, Dormer CS, Wells T., PertP., Price CA, Buckley P. (1988). Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole. Toxicol Pathol 16: 2—98.
• Colin-Jones DG, Langman MJS, Lawson DH, Vessey MP (1985). Post-marketing surveillance of the safety of cimetidine: Mortality during second, third and fourth years of follow-up. Br Med J 291: 1084—1088.[Abstract/Free Full Text]
• Delle Fave G., Helander H., Holt S., Modlin IM, Powers R., Solcia E., Soll A., Tielemans Y., Wright NA (1994). Acid suppression and gastric mucosal cell biology. Dig Dis Sci 39: 9—52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Eissele R., Arnold R. (1993). Risiko der Entwicklung von Tumoren unter der Therapie mit dem Protonenpumpen-Inhibito r Omeprazol (Risk for developing tumors in therapy with the proton pump inhibitor Omeprazole). Versicherungsmedizin 45(4): 126—129.[Medline] [Order article via Infotrieve]
• Ekman L., Hansson E., Havu N., Carlsson E., Lundberg C. (1985). Toxicological studies on omeprazole. Scand J Gastroenterol Suppl 108: 53.
• Emminger A., Mohr U. ( 1982). Tumours of the oral cavity, cheek pouch, salivary glands, oesophagus, stomach and intestines. In: Pathology of Tumours in Laboratory Animals—Tumours of the Hamster, Turusov V (ed). IARC scientifi cpublications, Lyon, pp 45—50.
• Greaves P. (1990). VII. Digestive system 1. In: Histopathology ofPreclinical Toxicity Studies—Interpretation and Relevance in Drug Safety Evaluation, Elsevier, Amsterdam, pp 321—325.
• Hakanson R., Chen D., Andersson K., Monstein HJ, Zhao CM, Ryberg B., Sundler F., Mattsson H. (1994a). The biology and physiology of the ECL cell. Yale J Biol Med 67: 3— 4.
• Hakanson R., Chen D., Tielemans Y., Andersson K., Ryberg B., Sundler F., Mattsson H. (1994b). ECL cells: Biology and pathobiology. Digestion 55 (suppl 3): 38— 45.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Havu M., Mattson H., Ekman L., Carlsson E. (1990). Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of Ranitidine. Digestion 45: 189—195.[Web of Science][Medline] [Order article via Infotrieve]
• Head KW (1990). Tumours of the alimentary tract. In: Tumors in Domestic Animals, Moulton JE (ed). University of California Press, Berkeley, pp 45—50.
• Kokkola A., Sjoblom SM, Haapiainen R., Sipponen P., Puolakkainen P., Jarvinen H. (1998). The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia—A prospective follow-up study. Scand J Gastroentero l 33: 88—92.[CrossRef]
• Kolby L., Wangberg B., Ahlman H., Modlin IM, Granerus G., Theodorsson E., Nilsson O. (1996). Histidine decarboxylase expression and histamine metabolism in gastric oxyntic mucosa during hypergastrinemia and carcinoid tumor formation. Endocrinology 137: 4435— 4442.
• Kolby L., Wangberg B., Ahlman H., Modlin IM, Nilsson O. (1998). Histamine metabolism of gastric carcinoids in Mastomys natalensis. Yale J Biol Med 71: 207—215.[Web of Science][Medline] [Order article via Infotrieve]
• Larsson H., Hakanson R., Mattsson H., Ryberg B., Sundler F., Carlsson E. (1988). Omeprazole: Its infl uence on gastric acid secretion, gastrin and ECL cells. Toxicol Pathol 16: 2—72.
• Leininger JR, Jokinen MP (1994). Tumours of the oral cavity, pharynx, oesophagu s and stomach. In: Pathology of Tumours in Laboratory Animals— Tumours of the Mouse, Turusov V, Mohr U (eds). IARC Scientifi c Publications, Lyon, pp 167—194.
• Leininger JR, Jokinen MP, Dangler CA, Whiteley LO (1999). Oral cavity, esophagus, and stomach. In: Pathology of the Mouse, Maronpot RR, Boorman GA, Gaul BW (eds). Cache River Press, Vienna, IL, pp 42— 45.
• Levene H. (1960). Robust tests for equality of variances. In: Contributions to Probability and Statistics, Olkin et al. (eds). Stanford University Press, Stanford, CA, pp 278—292.
• LIoyd RV (1999). Immunohistochemical markers of endocrine/ neuroendocrin e tumors. J Histotechnol 22(3): 231—237.[Web of Science]
• Maekawa A., Enomoto M., Hirouchi Y., Yamakawa S. (1996). Changes in the upper digestive tract and stomach. In: Pathobiology of the Aging Mouse, Mohr U, Dungworth DL, Capen CC, Carlton WW, Sundberg JP, Ward JM (eds). ILSI Press, Washington, DC, pp 267—286.
• Mattsson H., Andersson K., Hakanson R., Larssson H., Sundler F., Wallmark B. (1988). Sex and species differences in plasma gastrin and gastrin-dependent variables. Studies in rats and mice during Omeprazole treatment. Gastroenterology 94(5): 2.
• Nilsson O., Wangberg B., Johansson L., Modlin IM, Ahlman H. (1992). Praomys (Mastomys) natalensis: A model for gastric carcinoid formation. Yale J Biol Med 65: 741 —751.[Web of Science][Medline] [Order article via Infotrieve]
• Oberg K., Janson ET, Eriksson B. (1999). Tumour markers in neuroendocrine tumours. Ital J Gastroenterol Hepatol 31(2): 160—162.
• Oh SW, Chae C., Jang D. ( 1997). Spontaneous gastric carcinoids tumors in the striped fi eld mouse (apodemus agrarius). J Vet Med Sci 59: 703—706.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Poynter D., Selway Sam, Papworth SA, Riches SR (1986). Changes in the gastric mucosa of the mouse associated with long-lasting insurmountable histamine H2 blockade. Gut 27: 1338—1346.[Abstract/Free Full Text]
• Rubin E., Farber JL (1994). The gastrointestinal tract. In: Pathology. J. B. Lippincott, Philadelphia, pp 668—670.
• SAS Institute, Inc. (1990). SAS/STAT User's Guide. Version 6, 4th ed. SAS Institute, Inc., Cary, NC.
• Spencer AJ, Barbolt TA, Henry DC, Eason CT, Sauerschell RJ, Bonner FW (1989). Gastric morphological changes including carcinoid tumors in animals treated with a potent hypolipidemic agent, ciprofi brate. Toxicol Pathol17(1): 1—15.[Web of Science][Medline] [Order article via Infotrieve]
• Streett CP, Robertson JL, Crissman JW (1988). Morphologic stomach fi ndings in rats and mice treated with the H2 receptor antagonists, ICI 125,211 and ICI 162,846. Toxicol Pathol 16: 299—304.[Web of Science][Medline] [Order article via Infotrieve]
• Takahashi M., Hasegawa R. (1990). Tumours of the stomach. In: Pathology of Tumours in Laboratory Animals—Tumours of the Rat, Turusov V, Mohr U (eds). IARC Scientifi c Publications, Lyon, pp 129— 135.
• Waldum HL, Brenna E., Sandvik AK (1998). Relationship of ECL cells and gastric neoplasia. Yale J Biol Med 71: 325—335.[Web of Science][Medline] [Order article via Infotrieve]
• Waldum HL, Kvetnoi IM, Sylte R., Schulze B., Martinsen TC, Sandvik AK (1998). The effect of the peroxisome proliferator ciprofi brate on the gastric mucosa and particularly the gastrin cell. J Mol Endocrin 20: 111— 117.[Abstract]
• Waldum HL, Sandvik AK, Idle JR ( 1998). Gastrin is the most important factor in ECL tumorigenesis. Gastroenterology 114: 1113— 1114.[CrossRef][Web of Science]
• Williams DA (1971). A test for differences between treatment means when several dose levels are compared with a zero dose control. Biometrics 27: 103—117.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Williams DA (1972). The comparison of several dose levels with a zero dose control. Biometrics 28: 519—531.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Zhao CM, Chen D., Lintunen M., Paula P., Hakanson R. (1999). Secretory organelles in ECL cells of the rat stomach: An immunohistochemical and electron-microscopic study. Cell Tissue Res 298(3): 457—470.[Web of Science][Medline] [Order article via Infotrieve]

Toxicologic Pathology, Vol. 30, No. 3, 322-327 (2002)
DOI: 10.1080/01926230252929891


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Thoolen, B. Articles by De Haan, M. Search for Related Content PubMed PubMed Citation Articles by Thoolen, B. Articles by De Haan, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Carcinoid Tumors Stomach Cancer Hazardous Substances DB OMEPRAZOLE Social Bookmarking                         What's this?